Hi Rasmus Gets $50M to Scale Autism Care Software

Hi Rasmus has secured a $50M strategic minority investment from Updata Partners, giving the ABA-first clinical software company its first disclosed outside capital after years of bootstrapped growth. Updata Partners VIII made the investment, and Updata General Partner Braden Snyder will join the Hi Rasmus board.

The transaction matters because applied behavior analysis providers are being asked to do two difficult things at once. They must keep care individualized around each child while producing clinical records, outcomes evidence, and operational visibility strong enough for supervisors, payers, and regulators. Hi Rasmus is building the software layer where those demands meet.

The company says it now serves more than 1,000 organizations across all 50 U.S. states and 90 countries, supports more than 19.6M hours of client sessions annually, and is onboarding two of the world's largest ABA providers. Those figures are company-reported, but they explain why a B2B software growth investor would see a platform ready for a larger enterprise push.

What Happened

Updata Partners announced that its eighth fund invested $50M in Hi Rasmus on September 3, 2026. Hi Rasmus described the transaction as a strategic minority investment, said founders retain majority ownership, and identified product innovation, AI, enterprise capabilities, integrations, clinical outcomes and research, team growth, infrastructure, and go-to-market expansion as priorities for the capital.

The parties did not disclose Hi Rasmus's valuation, the exact ownership stake, revenue, or additional investors. They also did not label the transaction as a Series round, making Strategic the most accurate subcategory. Hi Rasmus and Updata both describe the company as bootstrapped before the deal, so the $50M represents the first disclosed outside investment rather than another installment in a conventional venture sequence.

The governance change is clear. Braden Snyder, a General Partner at Updata, will join the Hi Rasmus board. Founder and CEO Nikolaj Hendriksen remains in charge, while the founders retain majority ownership.

The Product Was Built Around a Family's Care Experience

Hi Rasmus began with Hendriksen's experience navigating autism care for his son, Rasmus. The company's origin story is unusually close to the workflow it is trying to improve: families, clinicians, and educators can work hard around the same child while their information remains scattered across binders, systems, and handoffs.

The Hi Rasmus platform combines session data capture, treatment planning, clinical documentation, scheduling, care workflows, and outcomes reporting. It supports multiple ABA data types, customizable target workflows, offline collection, and secure photo and video capture. Enterprise teams can use shared programming and reporting across locations while supervisors monitor learner progress, staff performance, documentation quality, and outcomes.

Hi Rasmus is also adding AI-supported tools. Its AI Note Auditor, released in beta in July 2026, reviews completed session and supervision notes for gaps or inconsistencies that could create risk during a payer audit. The company says customer notes are not used to train shared models and that the feature operates within HIPAA-compliant controls.

Why the Timing Matters for ABA Providers

Clinical software in ABA has to carry more than scheduling and billing. A single session can generate treatment data, progress notes, supervision evidence, authorization support, and the documentation later used to explain why the care was medically necessary. When those records live in disconnected systems, clinicians absorb the friction and leadership loses a reliable view of what is happening across locations.

The policy environment is tightening around the same pressure. In August 2026, the Centers for Medicare & Medicaid Services released an ABA toolkit focused on individualized care, qualified providers, oversight, medical necessity, and program integrity. CMS reported that Medicaid and CHIP spending on ABA services increased 421% from 2021 through 2025, while the number of children with an autism diagnosis receiving services grew 67%.

That federal action is not an allegation against Hi Rasmus or its customers. It is evidence that providers, payers, and states need better ways to connect care delivery with documentation and outcomes. The Council of Autism Service Providers likewise treats clinical excellence, documentation, telehealth, business operations, and risk management as infrastructure problems for organizations delivering ABA services at scale.

What Updata Is Backing

Updata specializes in growth-stage B2B software and says it has more than $3B in committed capital. In Hi Rasmus, the firm is backing a vertical software company whose users do not merely log into a dashboard; they use the system while delivering care and creating the record that follows the session.

That distinction shapes the investment logic. Hi Rasmus reports more than 1,000 customer organizations, global distribution, and 19.6M annual session hours. Updata describes the business as rapidly growing and profitable, with strong retention and unit economics, although the investor did not disclose the underlying figures. The verified picture is a founder-led company that reached substantial scale before bringing an institutional investor into the ownership and governance structure.

The product agenda also reaches beyond basic clinical data collection. Hi Rasmus is investing in outcomes reporting, enterprise visibility, integrations, and AI tools intended to reduce documentation burden. CTO Mark Rosenvinge and the product organization now have additional resources to deepen those capabilities while the company expands its infrastructure and customer base.

The Operating Question Behind the $50M

Growth can make vertical software more useful because a larger customer base produces more edge cases, integration demands, and feedback. It can also make the company more complicated, especially when clinicians need the product to remain simple during a session and enterprise buyers need stronger controls around the same data.

Hi Rasmus must preserve that balance as it scales. The company can add AI, reporting, and enterprise features, but the product earns trust only when those layers help clinicians document care without turning the session into software administration. The outcome is also commercial: cleaner records and clearer outcomes can strengthen payer conversations, supervision, audit readiness, and the case for value-based care.

The $50M gives Hi Rasmus room to build across product, research, integrations, and go-to-market capacity. The work now moves into thousands of ordinary clinical moments where software either returns attention to the child or quietly takes more of it away.